● ʻOihana Pharmacogenetics
-
ʻO ka Polymorphism Genetic ALDH
Hoʻohana ʻia kēia pahu hana no ka ʻike qualitative in vitro o ka pūnaewele polymorphism ALDH2 gene G1510A i loko o ka DNA genomic koko peripheral kanaka.
-
ʻO ka Polymorphism Gene CYP2C9 kanaka a me VKORC1
He kūpono kēia pahu hana no ka ʻike ʻana i ka polymorphism o CYP2C9*3 (rs1057910, 1075A>C) a me VKORC1 (rs9923231, -1639G>A) ma ka DNA genomic o nā hāpana koko holoʻokoʻa kanaka.
-
ʻO ka Polymorphism Gene CYP2C19 kanaka
Hoʻohana ʻia kēia pahu no ka ʻike qualitative in vitro o ka polymorphism o nā genes CYP2C19 CYP2C19*2 (rs4244285, c.681G>A), CYP2C19*3 (rs4986893, c.636G>A), CYP2C19*17 (rs12248560, c.806>T) i loko o ka genomic DNA o nā hāpana koko holoʻokoʻa kanaka.
-
ʻAkika Nucleic B27 Leukocyte kanaka
Hoʻohana ʻia kēia pahu hana no ka ʻike ʻana i ka DNA ma nā ʻano antigen leukocyte kanaka HLA-B*2702, HLA-B*2704 a me HLA-B*2705.
-
ʻO ka waikawa nukleika polymorphic gene MTHFR
Hoʻohana ʻia kēia pahu hana e ʻike i nā wahi mutation 2 o ka gene MTHFR. Hoʻohana ka pahu hana i ke koko holoʻokoʻa kanaka ma ke ʻano he laʻana hoʻāʻo e hāʻawi i kahi loiloi qualitative o ke kūlana mutation. Hiki iā ia ke kōkua i nā kauka lapaʻau e hoʻolālā i nā hoʻolālā lapaʻau kūpono no nā ʻano pilikino like ʻole mai ka pae molekala, i mea e hōʻoia ai i ke olakino o nā maʻi i ka nui loa.
